共 50 条
- [31] Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS StudyANNALS OF HEMATOLOGY, 2025, 104 (01) : 515 - 525Fu, WeijunBang, Soo-MeeHuang, HonghuiKim, KihyunLi, WeiAn, GangLee, Je-JungCai, ZhenJin, JieWang, YafeiChim, Chor SangCarson, RobinLiu, RuiZhao, ManChen, XiCui, CanchanHou, JianWang, Jianxiang
- [32] Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS StudyCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (06): : 446 - +Fu, WeijunBang, Soo-MeeHuang, HonghuiKim, KihyunLi, WeiAn, GangLee, Je-JungCai, ZhenJin, JieWang, YafeiLin, Tung-LiangChim, Chor SangQi, MingWang, JianpingLu, XiaolinSong, YangJia, BinYang, XueLiu, WenyuZhou, TianyuanYin, LuLi, YunanZhang, RenyiHou, JianWang, Jianxiang
- [33] Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trialLANCET, 2020, 395 (10218): : 132 - 141Mateos, Maria-VictoriaCavo, MicheleBlade, JoanDimopoulos, Meletios A.Suzuki, KenshiJakubowiak, AndrzejKnop, StefanDoyen, ChantalLucio, PauloNagy, ZsoltPour, LudekCook, MarkGrosicki, SebastianCrepaldi, AndreLiberati, Anna MarinaCampbell, PhilipShelekhova, TatianaYoon, Sung-SooIosava, GenadiFujisaki, TomoakiGarg, MamtaKrevvata, MariaChen, YingWang, JianpingKudva, AnupaUkropec, JonWroblewski, SusanQi, MingKobos, RachelSan-Miguel, Jesus
- [34] Real-Life Experience of the Combination of Daratumumab, Bortezomib, Melphalan, and Prednisone (DVMP) in Patients with Newly Diagnosed Multiple Myeloma Ineligible for Autologous Stem-Cell TransplantationBLOOD, 2023, 142Domingo-Gonzalez, AmaliaAlonso Fernandez, RafaelJimenez, AnaDe Soto Alvarez, TeresaLerma, AnaPradillo Fernandez, VirginiaBenzo Callejo, GonzaloSanchez-Pina, JoseLandete, ElenaVelasco, AlbertoMenendez Cuevas, MarinaLopez Rinon, Monica MariaRamirez Lopez, AndresLopez Garcia, AlbertoBlanchard, Maria-JesusAskari, Elham
- [35] Bortezomib plus melphalan and prednisone (VMP) in elderly untreated patients with multiple myeloma:: Prognostic factors influencing time to progressionHAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 148 - 149Mateos, M.-V. M.Hernandez, J.-M.Hemandez, M.-T.Gutierrez, N.-C.Palomera, L.Fuertes, M.Garcia, P.Lahuerta, J. J.De la Rubia, J.Terol, M. J.Sureda, A.Bargay, J.Ribas, P.De Arriba, E.Alegre, A.Oriol, A.Carrera, D.Garcia-Larana, J.Garcia-Sanz, R.Bladé, J.Prosper, F.Esseltine, D.-L.Van de Velde, H.San-Miguel, J.-F.
- [36] Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching AnalysisAdvances in Therapy, 2020, 37 : 4996 - 5009Vania HungriaDeborah M. Martínez-BañosMaría-Victoria MateosMeletios A. DimopoulosMichele CavoBart HeegAndrea GarciaAnnette LamGerardo MachnickiJianming HeMariana Fernandez
- [37] Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching AnalysisADVANCES IN THERAPY, 2020, 37 (12) : 4996 - 5009Hungria, VaniaMartinez-Banos, Deborah M.Mateos, Maria-VictoriaDimopoulos, Meletios A.Cavo, MicheleHeeg, BartGarcia, AndreaLam, AnnetteMachnicki, GerardoHe, JianmingFernandez, Mariana
- [38] Subgroup Analyses of Progression-Free Survival from the Phase 3 Octans and Alcyone Studies in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Bortezomib, Melphalan, and Prednisone with or without DaratumumabBLOOD, 2023, 142Fu, WeijunBang, Soo-MeeHuang, HonghuiKim, KihyunLi, WeiAn, GangLee, Je-JungCai, ZhenJin, JieWang, YafeiChim, Chor SangOtero, Paula RodriguezDimopoulos, Meletios A.Fujisaki, TomoakiLee, Jae HoonWroblewski, SusanBorgsten, FredrikCarson, RobinLiu, RuiZhao, ManWu, TingtingChen, XiCui, CanchanHou, JianWang, Jianxiang
- [39] Reduced Dose-Intensity Subcutaneous Bortezomib Plus Prednisone (VP) Or Plus Cyclophosfamide (VCP) Or Plus Melphalan (VMP) For Newly Diagnosed Multiple Myeloma Patients Older Than 75 Years Of AgeBLOOD, 2013, 122 (21)Larocca, AlessandraCavallo, FedericaMagarotto, ValeriaOffidani, MassimoFederico, VincenzoInnao, VanessaFalcone, Antonietta PiaRomano, AlessandraCaravita, TommasoRossi, DavideMansueto, GiovannaMina, RobertoNozzoli, ChiaraBenevolo, GiuliaGuglielmelli, TommasinaLiberati, Anna MarinaDerudas, DanieleOliva, StefaniaMorabito, FortunatoCarella, Angelo MicheleGentili, SilviaSaraci, ElonaPetrucci, Maria TeresaSonneveld, PieterBoccadoro, MarioPalumbo, Antonio
- [40] A randomized open-label study of bortezomib, melphalan, and prednisone (VMP) versus daratumumab (DARA) plus VMP in patients with previously untreated multiple myeloma (MM) who are ineligible for high-dose therapy: 54767414MMY3007 (Alcyone).JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Mateos, Mara-VictoriaCavo, MicheleJakubowiak, Andrzej J.Carson, Robin L.Qi, MingBandekar, RajeshCrist, WendyAhmadi, TahamtanSan Miguel, Jesus F.